Data / Form D filings / Cyrus Biotechnology, Inc.
Cyrus Biotechnology, Inc.: Form D filings
Cyrus Biotechnology, Inc., a biotechnology company in Seattle, WA, filed 13 Form D notices with the SEC between 2015 and 2026. The latest, on May 8, 2026, reports $1.5 million sold of a $3 million offering to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3005 1ST AVE SUITE 203, Seattle, WA, 98121
- Phone
- (206) 258-6561
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1641241
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | Amendment | $3,000,000 | $1,481,812 | $1,518,188 | 17 | Jul 1, 2025 | sec.gov |
| Jul 16, 2025 | New notice | $1,500,000 | $1,110,000 | $390,000 | 12 | Jul 1, 2025 | sec.gov |
| Dec 31, 2024 | New notice | $3,500,000 | $3,183,997 | $316,003 | 27 | Oct 29, 2024 | sec.gov |
| Feb 29, 2024 | New notice | $4,000,000 | $2,694,470 | $1,305,530 | 33 | Feb 27, 2024 | sec.gov |
| Dec 2, 2021 | Amendment | $19,352,692 | $18,352,692 | $1,000,000 | 34 | Jun 22, 2021 | sec.gov |
| Oct 6, 2021 | Amendment | $15,942,168 | $15,942,168 | 35 | Jun 22, 2021 | sec.gov | |
| Jul 7, 2021 | New notice | $12,942,155 | $9,101,757 | $3,840,398 | 25 | Jun 22, 2021 | sec.gov |
| Sep 17, 2020 | New notice | $1,500,000 | $1,131,000 | $369,000 | 19 | Sep 4, 2020 | sec.gov |
| Jul 27, 2017 | New notice | $8,045,000 | $8,024,611 | $20,389 | 18 | Jul 13, 2017 | sec.gov |
| Feb 21, 2017 | New notice | $1,250,000 | $1,040,000 | $210,000 | 13 | Feb 13, 2017 | sec.gov |
| Nov 16, 2016 | New notice | $500,000 | $490,000 | $10,000 | 14 | Nov 7, 2016 | sec.gov |
| Apr 6, 2016 | New notice | $575,000 | $535,000 | $40,000 | 14 | Mar 23, 2016 | sec.gov |
| May 6, 2015 | New notice | $850,000 | $850,000 | 12 | Apr 22, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Lucas Nivon | Executive Officer, Director | |
| Mark Benjamin | Executive Officer | |
| Yifan Song | Director | |
| Chad Waite | Director | |
| Anthony Manning | Director | |
| Ramakrishna Satyavolu | Director | |
| Jason Smith | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of May 4, 2026 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cyrus Biotechnology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.